• Filter by client profile:
  • gender |
  • age |
  • accommodation situation |
  • with whom living |
  • education status |
  • employment status |
  • new client |
  • inpatient |
  • outpatient
• Filter by drug type:
  • amphetamines|
  • cannabis |
  • cocaine |
  • ecstasy |
  • heroin |
  • hallucinogens |
  • hypnotics/sedatives |
  • volatiles |
  • 'other drugs'
• Filter by patterns of use:
  • age at first use |
  • frequency of use |
  • primary drug |
  • secondary drug |
  • route of administration

displaying all

Category	Title
EYE	EYE-1. Cannabis prevalence rates Part (i) Lifetime, last year and last month prevalence of cannabis use among 15/16 year old school students (%), 2007
EYE	EYE-1. Cannabis prevalence rates Part (ii) Lifetime prevalence of cannabis use among 15/16 year old school students (%), 1995, 1999, 2003 and 2007
EYE	EYE-1. Cannabis prevalence rates Part (iii) Male and female lifetime prevalence of 40 or more cannabis uses among 15/16 year old school students (%), 2007
EYE	EYE-1. Cannabis prevalence rates Part (iv) Current (last month) prevalence of cannabis use among 15/16 and 17/18 year old school students' (%), 2003
EYE	EYE-1. Cannabis prevalence rates Part (v) Lifetime prevalence of cannabis use and perceived great risk among 15/16 year olds school students (%), 2007
EYE	EYE-1. Cannabis prevalence rates Part (vi) Lifetime prevalence for cannabis and ecstasy use with easy availability among 15/16 school students (%), 2007
EYE	EYE-1. Cannabis prevalence rates Part (vii) Reports of first use of cannabis aged 13 years or younger among 15/16 year old school students (%), 1999, 2003, 2007
EYE	EYE-1. Cannabis prevalence rates Part (viii) Lifetime prevalence of cannabis use and drinking 5 or more drinks in a row during past month among 15/16 year old school students (%), 2007
EYE	EYE-1. Cannabis prevalence rates Part (ix) Change in percentage lifetime prevalence of cannabis use among 15/16 year old school students, 1995-2007
EYE	EYE-1. Cannabis prevalence rates Part (x) Change in percentage lifetime prevalence of cannabis use among 15/16 year old school students, 2003-2007
EYE	EYE-1. Cannabis prevalence rates Part (xi) Trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students: low prevalence countries, east and central European countries, west European countries, Slovenia and Croatia
EYE	EYE-1. Cannabis prevalence rates Part (xii) Comparision of trends in average (weighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in Europe, USA and Australia
EYE	EYE-1. Cannabis prevalence rates Part (xiii) Trends in average (unweighted) lifetime prevalence of cannabis (%) among 15-16 year old school students in four country groups
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (i) Changes in lifetime prevalence of ecstasy use among 15/16 year old school students (%), 1995-2007
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (ii) Changes in lifetime prevalence of ecstasy use among 15/16 year old school students (%), 2003–07
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (iii) Lifetime prevalence of ecstacy use and perceived great risk among 15/16 year olds school (%), 2007
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (iv) Last month prevalence of drinking 5+ alcoholic drinks in a row and perceived great risk among 15/16 year olds school (%), 2007
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (v) Lifetime prevalence for use of ecstasy, LSD and other hallucinogens and magic mushrooms among 15/16 year old students (%), 2007
EYE	EYE-2. Lifetime prevalence for drugs other than cannabis among school students Part (vi) Lifetime prevalence for use of ecstasy and amphetamines among 15/16 year old students (%), 2007
DUP	DUP-1. Prevalence of lifetime drug use among prisoners
DUP	DUP-2. Prevalence of lifetime injecting drug use among prisoners
HSR	HSR-1. Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2008 or most recent year available
PPP	PPP-1. Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2003–08
PDU	PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2003 to 2008 — last study available Part (i) Estimates of overall problem drug use
PDU	PDU-1. Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2003 to 2008 — last study available Part (ii) Estimates for problem opioid use
PDU	PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2003 to 2008 — last study available
PDU	PDU-3. Percentage of new and of young injectors reported in samples of injecting drug users tested for HIV or HCV — studies from 2006 to 2008
DUP	DUP-0. Prevalence of drug use among prisoners — Sources and bibliographic references
DUP	DUP-1. Prevalence of lifetime drug use among prisoners, 2000–08
DUP	DUP-2. Prevalence of lifetime injecting drug use among prisoners, 2000–08
DUP	DUP-3. Prevalence of drug use within prison among prisoners, 2000–08
DUP	DUP-4. Prevalence of injecting drug use within prison among prisoners, 2000–08
DUP	DUP-105. Prevalence (percentage) of drug use among prisoners in EU Member States and Norway – full listing of studies
TDI	TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2003 to 2008 Part (i) Percentage distribution by primary drug
TDI	TDI-1. Trend in estimated number of new clients entering treatment by primary drug used, from 2003 to 2008 Part (ii) Numbers of clients by primary drug
TDI	TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2008 in 28 EU Member States Part (i) New clients
TDI	TDI-2. New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants, other drugs in 2008 in 28 EU Member States Part (ii) All clients
TDI	TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2003 to 2008 Part (i) Percentage distribution by primary drug
TDI	TDI-3. Trend in estimated number of all clients entering treatment by primary drug used, from 2003 to 2008 Part (ii) Numbers of clients by primary drug
TDI	TDI-7. New outpatient clients injecting opioid as primary drug from 2003 to 2008 in 13 countries supplying data
DLO	DLO-1. Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States 2003–08
DLO	DLO-2. Offence types in reports for drug law offences in Europe, 2007 or 2008
DLO	DLO-3. Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2003–08
DLO	DLO-4. Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2003–08
HSR	HSR-2. Estimated number of clients in opioid substitution treatment (OST) in EU 15–12, 1993–2008
HSR	HSR-3. Syringes distributed through specialised programmes per estimated IDU in 2008 or more recent year
HSR	HSR-4. Proportion of prison population receiving opioid substitution treatment (OST), 2008
SZR	SZR-1. Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2001-2008
GPS	GPS-0. Nationwide surveys among the general population: Bibliographic references
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Survey methods: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Lifetime prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Lifetime prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-1. Lifetime prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Lifetime prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 12 months prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 12 months prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-2. Last 12 months prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 12 months prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 30 days prevalence all adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 30 days prevalence young adults: last survey available for each Member State (from 2000 onwards)
GPS	GPS-3. Last 30 days prevalence of drug use in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 30 days prevalence 15 to 24 years old: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Lifetime prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Lifetime prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Lifetime prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Lifetime prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Lifetime prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-4. Lifetime prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Lifetime prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 12 months prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 12 months prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 12 months prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Last 12 months prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Last 12 months prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-5. Last 12 months prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Last 12 months prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (i) Last 30 days prevalence all adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (ii) Last 30 days prevalence all adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iii) Last 30 days prevalence young adults males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (iv) Last 30 days prevalence young adults females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (v) Last 30 days prevalence 15 to 24 years old males: last survey available for each Member State (from 2000 onwards)
GPS	GPS-6. Last 30 days prevalence of drug use by gender in nationwide surveys among the general population: last survey available for each Member State (from 2000 onwards) Part (vi) Last 30 days prevalence 15 to 24 years old females: last survey available for each Member State (from 2000 onwards)
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (i) Survey methods: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (ii) Lifetime prevalence all adults: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (iii) Lifetime prevalence young adults: all surveys
GPS	GPS-7. Lifetime prevalence of drug use in nationwide surveys among the general population Part (iv) Lifetime prevalence 15 to 24 years old: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (i) Last 12 months prevalence all adults: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (ii) Last 12 months prevalence young adults: all surveys
GPS	GPS-8. Last 12 months prevalence of drug use in nationwide surveys among the general population Part (iii) Last 12 months prevalence 15 to 24 years old: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (i) Last 30 days prevalence all adults: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (ii) Last 30 days prevalence young adults: all surveys
GPS	GPS-9. Last 30 days prevalence of drug use in nationwide surveys among the general population Part (iii) Last 30 days prevalence 15 to 24 years old: all surveys
GPS	GPS-10. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (i) Frequency of use among all users in last 30 days (percentage) — 2007 field trial
GPS	GPS-10. Frequency of use of cannabis among all adults (aged 15 to 64 years) and young adults (aged 15 to 34 years) in nationwide surveys among the general population Part (ii) Frequency of use among all users in last 30 days (percentage) — 2004 field trial
GPS	GPS-121. Methodological information for nation-wide surveys among the general population
EYE	EYE-0. School surveys: Sources
EYE	EYE-10. Recent school surveys (2005–2008): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
EYE	EYE-11. School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
EYE	EYE-20. ESPAD 2007 school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (i) All students
EYE	EYE-20. ESPAD 2007 school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (ii) Males
EYE	EYE-20. ESPAD 2007 school surveys:percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (iii) Females
EYE	EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (i) All students
EYE	EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (ii) Males
EYE	EYE-21. ESPAD 2007 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Part (iii) Females
EYE	EYE-22. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (i) All students
EYE	EYE-22. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (ii) Males
EYE	EYE-22. All ESPAD school surveys: percentage lifetime prevalence of psychoactive substance use among students 15–16 years Part (iii) Females
EYE	EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (i) All students
EYE	EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (ii) Males
EYE	EYE-23. All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Part (iii) Females
EYE	EYE-30. Recent school surveys (2003-2008): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old
SZR	SZR-1. Number of cannabis resin seizures, 1995 to 2008
SZR	SZR-2. Quantities (kg) of cannabis resin seized, 1995 to 2008
SZR	SZR-3. Number of herbal cannabis seizures, 1995 to 2008
SZR	SZR-4. Quantities (kg) of herbal cannabis seized, 1995 to 2008
SZR	SZR-5. Number of seizures of cannabis plants, 1995 to 2008
SZR	SZR-6. Quantities (number of plants) of cannabis plants seized, 1995 to 2008
SZR	SZR-7. Number of heroin seizures 1995 to 2008
SZR	SZR-8. Quantities (kg) of heroin seized 1995 to 2008
SZR	SZR-9. Number of cocaine seizures 1995 to 2008
SZR	SZR-10. Quantities (kg) of cocaine seized 1995 to 2008
SZR	SZR-11. Number of amphetamine seizures 1995 to 2008
SZR	SZR-12. Quantities (kg) of amphetamine seized 1995 to 2008
SZR	SZR-13. Number of ecstasy seizures 1995 to 2008
SZR	SZR-14. Quantities (tablets) of ecstasy seized 1995 to 2008
SZR	SZR-15. Number of LSD seizures 1995 to 2008
SZR	SZR-16. Quantities (units) of LSD seized 1995 to 2008
SZR	SZR-17. Number of methamphetamine seizures, 2001 to 2008
SZR	SZR-18. Quantities (kg) of methamphetamine seized, 2001 to 2008
INF	INF-0. Bibliographic references
INF	INF-1. Prevalence of HIV infection among injecting drug users in the EU, 2008 or most recent year available — Summary table by country.
INF	INF-2. Prevalence of HCV antibody among injecting drug users in the EU, 2008 or most recent year available — Summary table by country.
INF	INF-3. Prevalence of markers for HBV infection among injecting drug users in the EU, 2008 or most recent year available — Summary table by country
INF	INF-104. HIV infections newly diagnosed and AIDS incidence among injecting drug users, by country and year of diagnosis Part (i) (a) cases per million population, (b) number of cases and (c) population sizes, 1993 to 2008
INF	INF-105. Notified cases of hepatitis C infection among injecting drug users in the EU: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF	INF-106. Notified cases of hepatitis B infection among injecting drug users in the EU: a) Total number of cases where transmission route known, b) number of IDU cases, and c) percentage of IDUs amongst all cases with known risk factor
INF	INF-107. Incidence studies of hepatitis C virus infection among injecting drug users in the EU
INF	INF-108. Prevalence of HIV infection among injecting drug users (%), 1991 to 2008
INF	INF-109. Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2008
INF	INF-110. Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2008
INF	INF-111. Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2008
INF	INF-112. Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2008
INF	INF-113. Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2008
INF	INF-114. Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2008
INF	INF-115. Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2008
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2008 Part (i) Prevalence of HIV infection (percentage) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2008 Part (ii) Prevalence of hepatitis C infection (percentage) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2008 Part (iii) Prevalence of current hepatitis B infection (percentage with HBsAg) among injecting drug users in prison
INF	INF-117. Prevalence of HIV, HCV and HBV among drug users in prison, 1991 to 2008 Part (iv) Prevalence of antibodies against hepatitis B virus (percentage) among injecting drug users in prison
DRD	DRD-0. Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (i) Demographic characteristics, 2008 or last year with available information
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (ii) Numbers of drug-induced deaths and toxicology, 2008 or last year with available information
DRD	DRD-1. Summary of characteristics of the deceased in drug-induced deaths according to national definitions Part (iii) Demographic characteristics and toxicology, 1990 or earliest year with available information
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1995 to 2008
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Male drug-induced deaths, 1995 to 2008
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iii) Female drug-induced deaths, 1995 to 2008
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (iv) Total drug-induced deaths under the age of 25 years, 1995 to 2008
DRD	DRD-2. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (v) Totals and indexes, 1995 to 2008
DRD	DRD-3. Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2008
DRD	DRD-4. Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2008
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (i) Population mortality rates, 2008 or last year with available information
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (ii) Proportional mortality due to drug-induced deaths, 2008 or last year with available information
DRD	DRD-5. Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Part (iii) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
DRD	DRD-106. Methodological features of drug-induced deaths reported by Reitox national focal points (Based on national definitions – Reitox Standard Table 5).
DRD	DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (i) Total drug-induced deaths, 1985 to 2008
DRD	DRD-107. Number of drug-induced deaths recorded in EU Member States according to national definitions Part (ii) Totals and indexes, 1985 to 2008
DRD	DRD-108. Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2009 National reports)
DLO	DLO-1. Drug law offences, 1995 to 2008 Part (i) Number of reports of offences
DLO	DLO-1. Drug law offences, 1995 to 2008 Part (ii) Number of reports of persons
DLO	DLO-1. Drug law offences, 1995 to 2008 Part (iii) Methodological notes
DLO	DLO-2. Offence types in reports for drug law offences, 2007 or 2008 Part (i) Number and percentage of all reports for drug law offences
DLO	DLO-2. Offence types in reports for drug law offences, 2007 or 2008 Part (ii) Methodological notes
DLO	DLO-3. Drug types in reports for drug law offences, 2007 or 2008 Part (i) Number and percentage of all reports for drug law offences
DLO	DLO-3. Drug types in reports for drug law offences, 2007 or 2008 Part (ii) Methodological notes
DLO	DLO-4. Drug law offences related to drug use or possession for use, 2001 to 2008 Part (i) Number and percentage
DLO	DLO-4. Drug law offences related to drug use or possession for use, 2001 to 2008 Part (ii) Methodological notes
DLO	DLO-5. Drug law offences related to drug supply, 2001 to 2008 Part (i) Number and percentage
DLO	DLO-5. Drug law offences related to drug supply, 2001 to 2008 Part (ii) Methodological notes
DLO	DLO-6. Cannabis-related offences, 2001 to 2008 Part (i) Number and percentage of all drug law offences
DLO	DLO-6. Cannabis-related offences, 2001 to 2008 Part (ii) Methodological notes
DLO	DLO-7. Heroin-related offences, 2001 to 2008 Part (i) Number and percentage of all drug law offences
DLO	DLO-7. Heroin-related offences, 2001 to 2008 Part (ii) Methodological notes
DLO	DLO-8. Cocaine-related offences, 2001 to 2008 Part (i) Number and percentage of all drug law offences
DLO	DLO-8. Cocaine-related offences, 2001 to 2008 Part (ii) Methodological notes
DLO	DLO-109. Number of reports for drug law offences, 1985 to 2008 Part (i) Number of reports of offences
DLO	DLO-109. Number of reports for drug law offences, 1985 to 2008 Part (ii) Number of reports of persons
DLO	DLO-109. Number of reports for drug law offences, 1985 to 2008 Part (iii) Methodological notes
HSR	HSR-1. Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine
HSR	HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (i): Estimates of clients in methadone treatment or opioid substitution in EU-27, Croatia, Turkey and Norway, 1993–2008
HSR	HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (ii) Estimates and share of clients in methadone (MMT) and high-dosage buprenorphine (HDBT) treatment in EU-27, Croatia, Turkey and Norway in 2008
HSR	HSR-3. Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Part (iii) Methodological notes EU-27, Croatia, Turkey and Norway, 2003–2008
HSR	HSR-4. Year of introduction of needle and syringe programmes (NSPs) and types of programmes available in 2008
HSR	HSR-5. Syringes provided through needle and syringe programmes (NSPs), 2003, 2005, 2007 and 2008
HSR	HSR-6. Hepatitis B immunization in EU 27, Croatia, Turkey and Norway
HSR	HSR-8. Responses to drug related deaths in Europe Part (i) Provision of selected responses to reduce drug related deaths in 26 EU countries, Norway and Turkey in 2008 (expert ratings)
HSR	HSR-8. Responses to drug related deaths in Europe Part (ii). Availability of information material on drug-related deaths and emergencies for specific target groups in 26 EU countries, Norway and Turkey in 2008
HSR	HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway in 2008 Part (i) Legal framework regarding the initiation of OST by substitution medication
HSR	HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway in 2008 Part (ii) Legal framework regarding the continuation of OST by substitution medication
HSR	HSR-2. Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway in 2008 Part (iii) Legal framework regarding the dispensing of substitution medications
HSR	HSR-7. Health responses in prison Part (i) Level of provision of selected health responses to prisoners in 26 EU countries, Norway and Turkey in 2008 (expert ratings)
HSR	HSR-7. Health responses in prison Part (ii) Availability of specific responses to prisoners in 26 EU countries, Norway and Turkey in 2008 (expert ratings)
PDU	PDU-0. Estimates of prevalence of problem drug use at national and subnational level: bibliographic references
PDU	PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2003–08, rate per 1000 aged 15–64 Part (i) Overall problem drug use
PDU	PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2003–08, rate per 1000 aged 15–64 Part (ii) Injecting drug use
PDU	PDU-1. Estimates of prevalence of problem drug use at national level: summary table, 2003–08, rate per 1000 aged 15–64 Part (iii) Problem opioid use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2003 to 2008 (rate per 1 000 population aged 15 to 64): combined estimates per country Part (i) Estimated trends of overall problem drug use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2003 to 2008 (rate per 1 000 population aged 15 to 64): combined estimates per country Part (ii) Estimated trends of problem opioid use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2003 to 2008 (rate per 1 000 population aged 15 to 64): combined estimates per country Part (iii) Estimated trends of injecting drug use
PDU	PDU-6. Estimated trends in the prevalence of problem and injecting drug use, 2003 to 2008 (rate per 1 000 population aged 15 to 64): combined estimates per country Part (iv) Estimated trends of problem stimulant use
PDU	PDU-102. Prevalence of problem drug use at national level — full listing of studies Part (i) Problem drug use
PDU	PDU-102. Prevalence of problem drug use at national level — full listing of studies Part (ii) Injecting drug use
PDU	PDU-103. Prevalence of problem drug use at subnational level — full list of studies Part (i) Problem drug users
PDU	PDU-103. Prevalence of problem drug use at subnational level — full list of studies Part (ii) Injecting drug users
PDU	PDU-104. Trends in injecting drug use — percentage currently injecting among all clients entering treatment for primary drug heroin, 2003 to 2008
PDU	PDU-105. Studies of IDU providing information on sample structure by age and years injecting Part (i) IDUs distribution by age
PDU	PDU-105. Studies of IDU providing information on sample structure by age and years injecting Part (ii) IDUs distribution by years injecting
GPS	GPS-1. Last 12 months prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15- to 24-year-old age group, measured by national population surveys
GPS	GPS-2. Continuation rates of cannabis use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-3. Last 30 days prevalence of cannabis use among the 15-to 24-year old age group, measured by national surveys
GPS	GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (i) All countries
GPS	GPS-4. Trends in last 12 months prevalence of cannabis use among young adults (aged 15 to 34), measured by national surveys Part (ii) Countries with three or more surveys
GPS	GPS-5. Last 12 months prevalence of amphetamines use among young adults aged 15 to 34 and 15 to 24, measured by population surveys
GPS	GPS-6. Last 12 months prevalence of amphetamines use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-7. Last 30 days prevalence of cannabis use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group
GPS	GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-8. Trends in last 12 months use of amphetamines among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (i) All Member States with available information
GPS	GPS-9. Last 12 months prevalence of ecstasy use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24-year-old age group Part (ii) Males 15 to 24 in Member States with higher prevalence rates
GPS	GPS-10. Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W), measured by national population surveys
GPS	GPS-11. Continuation rates of ecstasy (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (i) Last 12 months prevalence in some of the EU-15 Member States
GPS	GPS-12. Last 12 months prevalence of cannabis use by age group in some Member States, measured by national population surveys — last survey available Part (ii) Last 12 months prevalence in some ‘new’ EU Member States
GPS	GPS-13. Last 12 months prevalence of cocaine use among all young adults (aged 15 to 34) by gender, measured by national surveys
GPS	GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-14. Trends in last 12 months prevalence of cocaine use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-15. Last 12 months prevalence of cocaine use among all adults (aged 15 to 64), young adults (aged 15 to 34) and for the 15 to 24 year age group, in some EU countries
GPS	GPS-16. Continuation rates of cocaine use (last 12 months and last 30 days use among lifetime users) in the general population, measured by national surveys
GPS	GPS-17. Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34)
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (i) Cannabis use — lifetime experience, last 12 months and last 30 days prevalence
GPS	GPS-18. Overview of drug prevalence estimates from various studies in Europe for all adults (aged 15 to 64) and young adults (aged 15 to 34) Part (ii) Cocaine, amphetamines and ecstasy use — lifetime experience, last 12 months and last 30 days prevalence
GPS	GPS-20. Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 to 34) in Europe, Canada, Australia and the USA — last survey available for each country
GPS	GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (i) All countries
GPS	GPS-21. Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 to 34), measured by population surveys Part (ii) Countries with three or more surveys
GPS	GPS-22. Continuation rates of amphetamines use (last 12 months and last 30 days use among lifetime users) in the general population, as measured by national surveys
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (i) United Kingdom (E&W)
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (ii) Denmark
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iii) Germany
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 to 34) in some Member States Part (iv) Spain
GPS	GPS-23. Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine among young adults (aged 15 to 34) in some Member States Part (v) France
INF	INF-1. AIDS incidence by year of diagnosis among injecting drug users by country, cases per million, 1998 to 2008
INF	INF-2. HIV infections newly diagnosed in injecting drug users, by country and year of diagnosis, cases per million, 2003–2008. EU countries, Croatia, Turkey and Norway. Part (i) HIV newly diagnosed cases per million population in IDUs, by year and by country — five highest EU countries in peak value 2003-2008
INF	INF-2. HIV infections newly diagnosed in injecting drug users, by country and year of diagnosis, cases per million, 2003–2008. EU countries, Croatia, Turkey and Norway. Part (ii) HIV newly diagnosed cases per million population in IDUs, by year and by country - other EU countries with peak > 1 case /M population 2003-2008
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2007 to 2008
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2007 to 2008
INF	INF-3. HIV prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2007 to 2008
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (i) All injecting drug users, 2007 to 2008
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (ii) Young injecting drug users (under age 25), 2007 to 2008
INF	INF-6. HCV antibody prevalence among injecting drug users — studies with national and subnational coverage Part (iii) New injecting drug users (injecting less than 2 years), 2007 to 2008
INF	INF-9. Prevalence of markers of HBV infection estimated among injecting drug users — studies with national and subnational coverage Part (i) Percentage positive for ever infected (aHBc), 2007 to 2008
INF	INF-9. Prevalence of markers of HBV infection estimated among injecting drug users — studies with national and subnational coverage Part (ii) Percentage positive for current infection (HBsAg), 2007 to 2008
DRD	DRD-1. Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
DRD	DRD-2. Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported
DRD	DRD-3. Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2008
DRD	DRD-4. Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2008
DRD	DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (i) Indexed trend in the EU-15 Member States and Norway 1990–2007
DRD	DRD-5. lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Part (ii) Indexed trend in the new Member States, 1990–2007
DRD	DRD-6. Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2007
DRD	DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Part (i) Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths
DRD	DRD-7. Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Part (ii) Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use
DRD	DRD-8. Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2007
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2008 (three-year moving average) Part (i) Some EU Member States and Norway, 1990 to 2008
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2008 (three-year moving average) Part (ii) Some EU Member States, 1990 to 2008
DRD	DRD-9. Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2008 (three-year moving average) Part (iii) Some EU countries, 1990 to 2008
DRD	DRD-10. Mean age of drug-induced deaths in EU Member States, last year with available data
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (i) Index in some Member States, 1985 to 2008
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (ii) Index in some Member States, 1985 to 2008
DRD	DRD-11. Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Part (iii) Index in some Member States, 1985 to 2008
DRD	DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Part (i) Changes between 2000 and 2003
DRD	DRD-12. Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Part (ii) Changes between 2003 and 2007/8
DRD	DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (i) EU-15 Member States and Norway 1990–2007
DRD	DRD-13. Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions Part (ii) New Member States, 1990–2007
HSR	HSR-9. Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway
PPP	PPP-1. Price of cannabis products at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP	PPP-1. Price of cannabis products at retail level, 2008 Part (ii) Sources of information
PPP	PPP-2. Price of heroin at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP	PPP-2. Price of heroin at retail level, 2008 Part (ii) Sources of information
PPP	PPP-3. Price of cocaine products at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP	PPP-3. Price of cocaine products at retail level, 2008 Part (ii) Sources of information
PPP	PPP-4. Price of synthetic drugs at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal price in euros
PPP	PPP-4. Price of synthetic drugs at retail level, 2008 Part (ii) Sources of information
PPP	PPP-5. Potency of cannabis products at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content
PPP	PPP-5. Potency of cannabis products at retail level, 2008 Part (ii) Sources of information
PPP	PPP-5. Potency of cannabis products at retail level, 2008 Part (iii) Sampling frame / Type of study
PPP	PPP-6. Purity of heroin at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
PPP	PPP-6. Purity of heroin at retail level, 2008 Part (ii) Sources of information
PPP	PPP-6. Purity of heroin at retail level, 2008 Part (iii) Sampling frame / Type of study / Purity determined to base-salt
PPP	PPP-7. Purity of cocaine products at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal purity recorded (percentage)
PPP	PPP-7. Purity of cocaine products at retail level, 2008 Part (ii) Sources of information
PPP	PPP-7. Purity of cocaine products at retail level, 2008 Part (iii) Sampling frame / Type of study / Purity determined to base-salt
PPP	PPP-8. Purity of synthetic drugs at retail level, 2008 Part (i) Minimum, maximum, mean, median and modal purity recorded
PPP	PPP-8. Purity of synthetic drugs at retail level, 2008 Part (ii) Sources of information
PPP	PPP-8. Purity of synthetic drugs at retail level, 2008 Part (iii) Sampling frame / Type of study
PPP	PPP-9. Composition of illicit drug tablets, 2008 Part (i) Content of synthetic scheduled illicit drugs
PPP	PPP-9. Composition of illicit drug tablets, 2008 Part (ii) Sources of information
PPP	PPP-9. Composition of illicit drug tablets, 2008 Part (iii) Sampling frame / Type of monitoring system
PPP	PPP-9. Composition of illicit drug tablets, 2008 Part (iv) Information available on substances listed in categories 'Miscellaneous' and 'Other'
PPP	PPP-10. Total drug-related labelled public expenditure 2005 and 2008
TDI	TDI-0. Data sources for clients entering treatment
TDI	TDI-1. Clients entering treatment and treatment units by country, 2008 or most recent year available
TDI	TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2008 Part (i) New clients by country and year of treatment
TDI	TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2008 Part (ii) All clients by country and year of treatment
TDI	TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2008 Part (iii) Reporting treatment units by country and year of treatment
TDI	TDI-2. Clients entering treatment and reporting treatment units, 1998 to 2008 Part (iv) Types of reporting treatment unit by country
TDI	TDI-3. New clients entering treatment by primary drug, 1998 to 2008 Part (i) New heroin clients by country and year of treatment (%)
TDI	TDI-3. New clients entering treatment by primary drug, 1998 to 2008 Part (ii) New cocaine clients by country and year of treatment (%)
TDI	TDI-3. New clients entering treatment by primary drug, 1998 to 2008 Part (iii) New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
TDI	TDI-3. New clients entering treatment by primary drug, 1998 to 2008 Part (iv) New cannabis clients by country and year of treatment (%)
TDI	TDI-4. Demographic characteristics of clients entering treatment, 2008 or most recent year available Part (i) New clients by country and gender (%)
TDI	TDI-4. Demographic characteristics of clients entering treatment, 2008 or most recent year available Part (ii) All clients by country and gender (%)
TDI	TDI-4. Demographic characteristics of clients entering treatment, 2008 or most recent year available Part (iii) New clients by country and age (%)
TDI	TDI-4. Demographic characteristics of clients entering treatment, 2008 or most recent year available Part (iv) All clients by country and age (%)
TDI	TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2008 or most recent year available Part (i) New clients by country and primary drug (%), regardless whether they inject the drug
TDI	TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All clients by country and primary drug (%), regardless whether they inject the drug
TDI	TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2008 or most recent year available Part (iii) New clients by country and rates of injection of primary drug (%)
TDI	TDI-5. Primary drug and rates of injection of primary drug of clients entering treatment, 2008 or most recent year available Part (iv) All clients by country and rates of injection of primary drug (%)
TDI	TDI-6. Incidence of treatment demand for drug use, 2008 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old)
TDI	TDI-7. Data coverage, 2008 or most recent year available Part (i) Clients entering treatment by country and type of treatment centre and type of client
TDI	TDI-7. Data coverage, 2008 or most recent year available Part (ii) Units by country and type of treatment centre and reporting status
TDI	TDI-8. Primary use of stimulants of clients entering treatment, 2008 or most recent year available Part (i) New clients by country and type of stimulant (%)
TDI	TDI-8. Primary use of stimulants of clients entering treatment, 2008 or most recent year available Part (ii) All clients by country and type of stimulant (%)
TDI	TDI-9. Demographic characteristics of clients entering outpatient treatment, 2008 or most recent year available Part (i) New outpatient clients by country and gender
TDI	TDI-9. Demographic characteristics of clients entering outpatient treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and by gender
TDI	TDI-9. Demographic characteristics of clients entering outpatient treatment, 2008 or most recent year available Part (iii) New outpatient clients by country and age
TDI	TDI-9. Demographic characteristics of clients entering outpatient treatment, 2008 or most recent year available Part (iv) All outpatient clients by country and age
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients, age distribution by primary drug (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (iii) All outpatient clients, age distribution by primary drug (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (v) New inpatient clients, age distribution by primary drug (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (vii) All inpatient clients, age distribution by primary drug (%)
TDI	TDI-10. Age distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients, age at first use distribution by primary drug (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (ii) New outpatient clients, primary drug distribution by age at first use (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (iii) All outpatient clients, age at first use distribution by primary drug (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (iv) All outpatient clients, primary drug distribution by age at first use (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (v) New inpatient clients, age at first use distribution by primary drug (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (vi) New inpatient clients, primary drug distribution by age at first use (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (vii) All inpatient clients, age at first use distribution by primary drug (%)
TDI	TDI-11. Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2008 or most recent year available Part (viii) All inpatient clients, primary drug distribution by age at first use (%)
TDI	TDI-12. Education status of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients by country and education status (%)
TDI	TDI-12. Education status of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and education status (%)
TDI	TDI-12. Education status of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by country and education status (%)
TDI	TDI-12. Education status of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by country and education status (%)
TDI	TDI-13. Labour status of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients by country and labour status (%)
TDI	TDI-13. Labour status of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and labour status (%)
TDI	TDI-13. Labour status of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by country and labour status (%)
TDI	TDI-13. Labour status of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by country and labour status (%)
TDI	TDI-14. Persons with whom client is living on entering treatment, 2008 or most recent year available Part (i) New outpatient clients by country and with whom living (%)
TDI	TDI-14. Persons with whom client is living on entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and with whom living (%)
TDI	TDI-14. Persons with whom client is living on entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by country and with whom living (%)
TDI	TDI-14. Persons with whom client is living on entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by country and with whom living (%)
TDI	TDI-15. Type of accommodation of clients entering treatment, 2008 or most recent year available Part (i) New clients entering outpatient treatment by country and type of accommodation (%)
TDI	TDI-15. Type of accommodation of clients entering treatment, 2008 or most recent year available Part (ii) All clients entering outpatient treatment by country and type of accommodation (%)
TDI	TDI-15. Type of accommodation of clients entering treatment, 2008 or most recent year available Part (iii) New clients entering inpatient treatment by country and type of accommodation (%)
TDI	TDI-15. Type of accommodation of clients entering treatment, 2008 or most recent year available Part (iv) All clients entering inpatient treatment by country and type of accommodation (%)
TDI	TDI-16. Source of referral of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients by country and source of referral (%)
TDI	TDI-16. Source of referral of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and source of referral (%)
TDI	TDI-16. Source of referral of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by country and source of referral (%)
TDI	TDI-16. Source of referral of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by country and source of referral (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (i) New opioid outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All opioid outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (iii) New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (iv) All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (vii) New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
TDI	TDI-17. Route of administration by primary drug of clients entering treatment, 2008 or most recent year available Part (viii) All hypnotics and sedatives outpatient clients by country and usual route of administration
TDI	TDI-18. Frequency of use of primary drug of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients by primary drug and frequency of use (%)
TDI	TDI-18. Frequency of use of primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by primary drug and frequency of use (%)
TDI	TDI-18. Frequency of use of primary drug of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by primary drug and frequency of use (%)
TDI	TDI-18. Frequency of use of primary drug of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by primary drug and frequency of use (%)
TDI	TDI-19. Primary drug of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients by country and primary drug (%)
TDI	TDI-19. Primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and primary drug (%)
TDI	TDI-19. Primary drug of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients by country and primary drug (%)
TDI	TDI-19. Primary drug of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients by country and primary drug (%)
TDI	TDI-21. Gender ratio by primary drug of clients entering treatment, 2008 or most recent year available Part (i) New outpatient clients, ratio of males to females by country and primary drug
TDI	TDI-21. Gender ratio by primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All outpatient clients, ratio of males to females by country and primary drug
TDI	TDI-21. Gender ratio by primary drug of clients entering treatment, 2008 or most recent year available Part (iii) New inpatient clients, ratio of males to females by country and primary drug
TDI	TDI-21. Gender ratio by primary drug of clients entering treatment, 2008 or most recent year available Part (iv) All inpatient clients, ratio of males to females by country and primary drug
TDI	TDI-22. Secondary drugs cited by clients entering treatment, 2008 or most recent year available Part (i) Outpatient units
TDI	TDI-22. Secondary drugs cited by clients entering treatment, 2008 or most recent year available Part (ii) Inpatient units
TDI	TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2008 or most recent year available Part (i) New clients by country and primary drug and type of treatment centre (%)
TDI	TDI-24. Type of treatment centre by primary drug of clients entering treatment, 2008 or most recent year available Part (ii) All clients by country and primary drug and type of treatment centre (%)
TDI	TDI-25. Age distribution of all clients entering outpatient treatment by primary drug and gender, 2008 or most recent year available
TDI	TDI-32. Mean age of clients entering treatment by primary drug and gender, 2008 or most recent year available Part (i) Outpatient clients
TDI	TDI-32. Mean age of clients entering treatment by primary drug and gender, 2008 or most recent year available Part (ii) Inpatient clients
TDI	TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2008 or most recent year available Part (i) Outpatient units
TDI	TDI-33. Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2008 or most recent year available Part (ii) Inpatient units
TDI	TDI-36. Primary amphetamine use among new clients entering treatment (%), 2003 to 2008
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available Part (i) All clients by country and primary drug and type of treatment unit
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available Part (ii) Outpatient clients by primary drug and mean age, gender ratio
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available Part (iii) Inpatient clients by primary drug and mean age, gender ratio
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available Part (iv) Outpatient clients by secondary drug and primary drug
TDI	TDI-37. Amphetamines and ecstasy clients entering drug treatment, 2008 or most recent year available Part (v) Inpatient clients by secondary drug and primary drug
TDI	TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (i) Number of clients by country, primary drug, and incidence/prevalence
TDI	TDI-38. Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (ii) Percentage of clients with known primary drug, by country, primary drug and incidence/prevalence
TDI	TDI-38. Table TDI-38: Clients in treatment by primary drug, all types of treatment centre, 2007 or most recent year available Part (iii) Percentage of clients injecting their primary drug by country, primary drug and incidence/prevalence
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (i) New opioid outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (vii) New cannabis outpatient clients by country and age
TDI	TDI-102. New clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (i) All opioid outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (vii) All cannabis outpatient clients by country and age
TDI	TDI-103. All clients entering outpatient treatment by primary drug and age, 2008 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (i) New opioid inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (iv) New hallucinogen inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (vii) New cannabis inpatient clients by country and age
TDI	TDI-104. New clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and by age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (i) All opioid inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (vii) All cannabis inpatient clients by country and age
TDI	TDI-105. All clients entering inpatient treatment by primary drug and age, 2008 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (i) New opioid outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (ii) New cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iii) New stimulants (other than cocaine) outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iv) New hallucinogen outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (v) New hypnotics and sedatives outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vi) New volatile inhalant outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vii) New cannabis outpatient clients by country and age at first use
TDI	TDI-106. New clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (viii) New 'other drugs' outpatient clients by country and by age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (i) All opioid outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (ii) All cocaine (HCI and 'crack') outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iii) All stimulants (other than cocaine) outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iv) All hallucinogen outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (v) All hypnotics and sedatives outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vi) All volatile inhalant outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vii) All cannabis outpatient clients by country and age at first use
TDI	TDI-107. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (viii) All 'other drugs' outpatient clients by country and by age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (i) New opioid inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (ii) New cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iii) New stimulants (other than cocaine) inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iv) Number of clients using hallucinogens as primary drug
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (v) New hypnotics and sedatives inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vi) New volatile inhalant inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vii) New cannabis inpatient clients by country and age at first use
TDI	TDI-108. New clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (viii) New 'other drugs' inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (i) All opioid inpatient clients by country and age at first
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (ii) All cocaine (HCI and 'crack') inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iii) All stimulants (other than cocaine) inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (iv) All hallucinogen inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (v) All hypnotics and sedatives inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vi) All volatile inhalant inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vii) All cannabis inpatient clients by country and age at first use
TDI	TDI-109. All clients entering inpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (viii) All 'other drugs' inpatient clients by country and by age at first use
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (i) New opioid outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (ii) All opioid outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (iii) New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (iv) All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (v) New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (vi) All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
TDI	TDI-111. All clients entering outpatient treatment by primary drug and age at first use, 2008 or most recent year available Part (vii) New cannabis outpatient clients by country and frequency of use (%)
TDI	TDI-111. Frequency of use of primary drug of clients entering outpatient treatment, 2008 or most recent year available Part (viii) All cannabis outpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (i) New opioid inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (ii) All opioid inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (iii) New cannabis inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (iv) All cannabis inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (v) New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (vi) All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (vii) New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI	TDI-112. Frequency of use of primary drug of clients entering inpatient treatment, 2008 or most recent year available Part (viii) All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
TDI	TDI-113. All clients entering treatment for opioids by country and type of opioid misused (%), 2007 or most recent year available
TDI	TDI-114. Primary opioids distribution (percent) among all clients entering treatment by country and type of treatment centre (%), 2008
TDI	TDI-115. HCL and crack use of clients entering outpatient treatment, 2008 or most recent year available Part (i) New outpatient clients by country and type of cocaine product
TDI	TDI-115. HCL and crack use of clients entering outpatient treatment, 2008 or most recent year available Part (ii) All outpatient clients by country and type of cocaine product
INF	INF-104. HIV infections newly diagnosed and AIDS incidence among injecting drug users, by country and year of diagnosis Part (ii) (a) AIDS incidence cases per million population, (b) number of cases and (c) population sizes, 1998 to 2008